Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OMCL 
Omnicell Inc (OMCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: OMCL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $46
1 Year Target Price $46
| 3 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 21.08% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.58B USD | Price to earnings Ratio 80.23 | 1Y Target Price 46 |
Price to earnings Ratio 80.23 | 1Y Target Price 46 | ||
Volume (30-day avg) 8 | Beta 0.84 | 52 Weeks Range 22.66 - 52.90 | Updated Date 11/5/2025 |
52 Weeks Range 22.66 - 52.90 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When Before Market | Estimate 0.36 | Actual 0.51 |
Profitability
Profit Margin 1.69% | Operating Margin (TTM) 2.94% |
Management Effectiveness
Return on Assets (TTM) 0.43% | Return on Equity (TTM) 1.63% |
Valuation
Trailing PE 80.23 | Forward PE 29.5 | Enterprise Value 1349885844 | Price to Sales(TTM) 1.35 |
Enterprise Value 1349885844 | Price to Sales(TTM) 1.35 | ||
Enterprise Value to Revenue 1.17 | Enterprise Value to EBITDA 13.14 | Shares Outstanding 45934251 | Shares Floating 44438387 |
Shares Outstanding 45934251 | Shares Floating 44438387 | ||
Percent Insiders 1.79 | Percent Institutions 104.84 |
Upturn AI SWOT
Omnicell Inc
Company Overview
History and Background
Omnicell, Inc. was founded in 1992. It initially focused on automated medication dispensing systems. Over time, it expanded its offerings through internal development and acquisitions to provide a broader suite of solutions for medication management and supply chain optimization in healthcare settings.
Core Business Areas
- Medication Management: Provides automated medication dispensing systems, inventory management software, and related services to help hospitals and pharmacies improve medication safety, efficiency, and compliance.
- Supply Chain Management: Offers solutions for managing medical supplies and equipment, including tracking inventory, optimizing purchasing, and streamlining logistics.
- Outpatient Pharmacy: Offerings for outpatient pharmacies, including automation solutions to improve efficiency and patient safety.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, and other executives responsible for various functional areas. The organizational structure likely includes departments for sales, marketing, research and development, operations, and finance.
Top Products and Market Share
Key Offerings
- XT Automated Dispensing System: Automated medication dispensing system for hospitals. Competitors include Becton Dickinson (BDX) and Capsa Healthcare. Market share for automated dispensing systems varies by region and specific product segment but Omnicell is a major player.
- iRx Workflow: Software platform that streamlines pharmacy workflows and improves medication management. Competitors include Cerner (Oracle) and Epic Systems. Revenue details are not publicly available.
- EnlivenHealth: A suite of pharmacy solutions designed to improve patient engagement and adherence. Competitors include DrFirst and RxSafe. Revenue details are not publicly available.
Market Dynamics
Industry Overview
The healthcare technology industry is experiencing growth driven by factors such as increasing healthcare costs, regulatory requirements, and the need for improved efficiency and patient safety. Automation and data analytics are key trends.
Positioning
Omnicell is a leading provider of medication management and supply chain solutions for healthcare providers. Its competitive advantages include a comprehensive product portfolio, a strong customer base, and a focus on innovation.
Total Addressable Market (TAM)
The total addressable market for medication management and supply chain solutions in healthcare is estimated to be in the billions of dollars globally. Omnicell is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Comprehensive product portfolio
- Strong customer relationships
- Focus on innovation
- Established market presence
- Scalable solutions
Weaknesses
- High product development costs
- Reliance on hospital capital spending
- Integration challenges with existing healthcare systems
- Susceptible to cyberattacks
Opportunities
- Expanding into new geographic markets
- Developing new solutions for outpatient pharmacies
- Leveraging data analytics to improve medication management
- Partnerships with other healthcare technology companies
- Increasing demand for telehealth services
Threats
- Increased competition from established players and new entrants
- Regulatory changes affecting medication management
- Cybersecurity threats
- Economic downturns impacting hospital budgets
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- BDX
- IMGN
- ATRC
- CPSI
- ALLO
Competitive Landscape
Omnicell's advantages include a comprehensive product portfolio and a strong customer base. Disadvantages may include higher product development costs. Competitors such as Becton Dickinson have broader healthcare offerings, while smaller companies may focus on niche markets.
Major Acquisitions
PharmAssist International
- Year: 2021
- Acquisition Price (USD millions): 113
- Strategic Rationale: Expanded Omnicellu2019s presence in the medication adherence space.
ReCept Holdings, Inc.
- Year: 2021
- Acquisition Price (USD millions): 290
- Strategic Rationale: Expand Omnicellu2019s presence in the alternate care space.
Growth Trajectory and Initiatives
Historical Growth: Omnicell's historical growth has been driven by organic expansion and strategic acquisitions. Refer to their Investor Relations page.
Future Projections: Future growth projections can be obtained from analyst reports and company guidance. These projections typically consider market trends, competitive dynamics, and strategic initiatives.
Recent Initiatives: Recent strategic initiatives may include new product launches, acquisitions, partnerships, and investments in research and development.
Summary
Omnicell is a major player in medication management, benefiting from a comprehensive product line. Competition and potential cybersecurity risks remain significant concerns. Strong sales and strategic acquisitions are working well and must be monitored, whereas integrating acquired solutions must be monitored. Future growth depends on continued innovation and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Omnicell Investor Relations
- Industry reports
- Analyst reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. It does not constitute financial advice. Market data and financial figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omnicell Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2001-08-07 | Founder, Executive Chairman, President & CEO Mr. Randall A. Lipps | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3670 | Website https://www.omnicell.com |
Full time employees 3670 | Website https://www.omnicell.com | ||
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.